2694 related articles for article (PubMed ID: 28444290)
1. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.
Ference BA; Ginsberg HN; Graham I; Ray KK; Packard CJ; Bruckert E; Hegele RA; Krauss RM; Raal FJ; Schunkert H; Watts GF; Borén J; Fazio S; Horton JD; Masana L; Nicholls SJ; Nordestgaard BG; van de Sluis B; Taskinen MR; Tokgözoglu L; Landmesser U; Laufs U; Wiklund O; Stock JK; Chapman MJ; Catapano AL
Eur Heart J; 2017 Aug; 38(32):2459-2472. PubMed ID: 28444290
[TBL] [Abstract][Full Text] [Related]
2. A Critical Review of the Consensus Statement from the European Atherosclerosis Society Consensus Panel 2017.
Okuyama H; Hamazaki T; Hama R; Ogushi Y; Kobayashi T; Ohara N; Uchino H
Pharmacology; 2018; 101(3-4):184-218. PubMed ID: 29353277
[TBL] [Abstract][Full Text] [Related]
3. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
[TBL] [Abstract][Full Text] [Related]
4. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
Rosenblit PD
Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
[TBL] [Abstract][Full Text] [Related]
5. 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.
Lloyd-Jones DM; Morris PB; Ballantyne CM; Birtcher KK; Daly DD; DePalma SM; Minissian MB; Orringer CE; Smith SC
J Am Coll Cardiol; 2017 Oct; 70(14):1785-1822. PubMed ID: 28886926
[TBL] [Abstract][Full Text] [Related]
6. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
[TBL] [Abstract][Full Text] [Related]
7. Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease.
Dixon DL; Pamulapati LG; Bucheit JD; Sisson EM; Smith SR; Kim CJ; Wohlford GF; Pozen J
Curr Atheroscler Rep; 2019 Mar; 21(5):16. PubMed ID: 30877491
[TBL] [Abstract][Full Text] [Related]
8. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
Circulation; 2019 Jun; 139(25):e1144-e1161. PubMed ID: 30586775
[TBL] [Abstract][Full Text] [Related]
9. Clinical implications of the log linear association between LDL-C lowering and cardiovascular risk reduction: Greatest benefits when LDL-C >100 mg/dl.
Robinson JG; Jayanna MB; Bairey Merz CN; Stone NJ
PLoS One; 2020; 15(10):e0240166. PubMed ID: 33119602
[TBL] [Abstract][Full Text] [Related]
10. 2017 Taiwan lipid guidelines for high risk patients.
Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Statin/Ezetimibe for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Asian Populations: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Bhagavathula AS; Aldhaleei WA; Al Matrooshi NO; Rahmani J
Clin Drug Investig; 2020 Sep; 40(9):809-826. PubMed ID: 32671595
[TBL] [Abstract][Full Text] [Related]
12. Simulation study on LDL cholesterol target attainment, treatment costs, and ASCVD events with bempedoic acid in patients at high and very-high cardiovascular risk.
Katzmann JL; Becker C; Bilitou A; Laufs U
PLoS One; 2022; 17(10):e0276898. PubMed ID: 36301892
[TBL] [Abstract][Full Text] [Related]
13. Statins and PCSK9 inhibitors: A new lipid-lowering therapy.
Gallego-Colon E; Daum A; Yosefy C
Eur J Pharmacol; 2020 Jul; 878():173114. PubMed ID: 32302598
[TBL] [Abstract][Full Text] [Related]
14. The therapeutic management of South African dyslipidaemic patients at very high cardiovascular risk (CARDIO TRACK): a cross-sectional study.
Blom DJ; Ranjith N; Joshi P; Naidoo P; van Tonder A; Musa MG; Joshi S; Leisegang R; Trokis JS; Makan H; Raal FJ
Cardiovasc J Afr; 2020; 31(5):245-251. PubMed ID: 33151240
[TBL] [Abstract][Full Text] [Related]
15. The 2018 Cholesterol Management Guidelines: Topics in Secondary ASCVD Prevention Clinicians Need to Know.
Jia X; Al Rifai M; Birnbaum Y; Smith SC; Virani SS
Curr Atheroscler Rep; 2019 Apr; 21(6):20. PubMed ID: 30941517
[TBL] [Abstract][Full Text] [Related]
16. Approach to patients with elevated low-density lipoprotein cholesterol levels.
Feingold KR; Chait A
Best Pract Res Clin Endocrinol Metab; 2023 May; 37(3):101658. PubMed ID: 35487874
[TBL] [Abstract][Full Text] [Related]
17. Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations.
Adhyaru BB; Jacobson TA
Curr Atheroscler Rep; 2017 Jun; 19(6):29. PubMed ID: 28500517
[TBL] [Abstract][Full Text] [Related]
18. The Projected Impact of Population-Wide Achievement of LDL Cholesterol <70 mg/dL on the Number of Recurrent Events Among US Adults with ASCVD.
McKinley EC; Bittner VA; Brown TM; Chen L; Exter J; Farkouh ME; Huang L; Jackson EA; Levitan EB; Orroth KK; Reading SR; Rosenson RS; Safford MM; Woodward M; Muntner P; Colantonio LD
Cardiovasc Drugs Ther; 2023 Feb; 37(1):107-116. PubMed ID: 34599698
[TBL] [Abstract][Full Text] [Related]
19. Adding ezetimibe to statin therapy: latest evidence and clinical implications.
Vavlukis M; Vavlukis A
Drugs Context; 2018; 7():212534. PubMed ID: 30023003
[TBL] [Abstract][Full Text] [Related]
20. Association Between Baseline, Achieved, and Reduction of CRP and Cardiovascular Outcomes After LDL Cholesterol Lowering with Statins or Ezetimibe: A Systematic Review and Meta-Analysis.
Zhang XL; Lan RF; Zhang XW; Xu W; Wang L; Kang LN; Xu B
J Am Heart Assoc; 2019 Aug; 8(16):e012428. PubMed ID: 31411090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
